Amyvid

Latest Headlines

Eli Lilly's Alzheimer's imaging agent, Amyvid, can't get very far sales-wise without coverage from the Center for Medicare and Medicaid Services (CMS). And as per a September decision, that's something it doesn't have. Now, however, it's fighting back, funding litigation it couldn't file itself.

Eli Lilly has some allies for a brewing fight with Medicare. Alzheimer's groups are ready to back Amyvid, the company's imaging agent, in hopes that the Centers for Medicare and Medicaid Services will decide to pay for a diagnostic test after all.

Medicare has put up a big roadblock to Eli Lilly's Alzheimer's screening product Amyvid. The Centers for Medicare & Medicaid Services says it will only pay for the diagnostic agent if patients using it are in clinical trials, at least for now.

While Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, this time in Europe.

While Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, this time in Europe.

Eli Lilly ($LLY) is on the verge of gaining approval in the European Union to use its radioactive diagnostic agent Amyvid as a tool to detect Alzheimer's related brain plaque buildup, 6months after U.S. regulators granted a similar approval.

Eli Lilly ($LLY) failed last year to gain the FDA's approval to use its radioactive diagnostic agent Amyvid for possible Alzheimer's patients. The second time around, it has finally obtained a positive regulatory sign-off, but for a more general indication.

THE LIBRARY: WEBINAR

This webinar will summarize the core scientific concepts needed to develop a global observational study protocol that describes or evaluates a therapeutic treatment in patients under conditions of usual care, in terms of clinical, humanistic and economic outcomes for a variety of key stakeholders. Register Today!